Get a real taste and understanding of the business and culture of one of the world's great research-based cellular and gene therapy discovery and development companies.
EXPLORE MORECreative Biolabs has a tradition of commitment. To achieve efficient execution and regulatory approval, we offer careful considerations of your program for the development of a cellular or gene therapy product – now and in the future.
EXPLORE MORE HighlightsWe focus on unmet needs and develop novel cellular and gene drugs and solutions that offer significant benefits over existing options.
EXPLORE MORE HighlightsTo accelerate advanced breakthroughs of your projects, we offer broad range of platforms which enable our clients be free to tackle problems with cutting-edge technologies from different angles and in different methods.
EXPLORE MORE HighlightsUse the resources in our library to help you understand your options and make critical decisions for your study. We offer oncolytic virus, CAR-T, and dendritic cell related documents, as well as newsletter. If you don't find the answers you're looking for, contact us for additional assistance.
EXPLORE MORE Highlights
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
The great success of chimeric antigen receptor (CAR)-T cells has prompted scientists to genetically modify human natural killer (NK) cells with CAR to better treat lethal cancer. NK cells can now be routinely produced from human pluripotent stem cells (PSC). These PSCs provide a novel resource that can be used to produce "off-the-shelf" NK cells with a homogeneous and standardized group for CAR-NK therapy.
At Creative Biolabs, we have developed the iPSC technology platform to produce NK cells derived from CAR-expressing stem cells. This technology platform provides an unlimited source of engineered stem cell-derived CAR-NK immune cells. These PSC-derived NK cells have similar phenotypes and functions to primary lymphocytes isolated from peripheral blood, thereby they can be precisely engineered to introduce the improved anti-tumor activity.
We provide multiple strategies to engineer iPSC-derived NK (iPSC-NK) cells for enhanced functional potential, persistence, and homing. Examples of such gene editing strategies include (i) strategies aimed at introducing specificity through cleavage-resistant CD16 to combine with therapeutic antibodies or CAR; (ii) strategies aimed at improving the persistence of allogeneic iPSC-NK cells by making cells self-sufficient in terms of growth factors; (iii) strategies aimed at co-expressing CXCR3 to enhance the iPSC-NK cell homing to tumor cells.
More customized gene editing strategies can be performed according to your requirements.
Fig.1 The potential of iPSC-derived NK cells as a template for engineering. (Saetersmoen, 2019)
HSC from a healthy donor are engineered using viral vectors that insert the CAR sequence in the cell genome.
The CAR-HSC is stimulated by cytokines to differentiate into NK cells, resulting in a population of CAR-NK cells that can be used for multiple patients
The CAR-NK cells infused in the patient selectively recognize the tumor cells expressing the antigen and mediate the killing.
As the leading cell therapeutics biotech that provides cell therapy related services, Creative Biolabs provides one-stop services for CAR-NK therpy development, including but not limit to:
If you are interested in our services, please send an email to contact us, and our team will get back to you as soon as possible.
Reference
For any technical issues or product/service related questions, please leave your information below. Our team will contact you soon.
NEWSLETTER
The latest newsletter to introduce the latest breaking information, our site updates, field and other scientific news, important events, and insights from industry leaders
LEARN MORE NEWSLETTER
NEW SOLUTION
CellRapeutics™ In Vivo Cell Engineering: One-stop in vivo T/B/NK cell and macrophage engineering services covering vectors construction to function verification.
LEARN MORE SOLUTION
NOVEL TECHNOLOGY
Silence™ CAR-T Cell: A novel platform to enhance CAR-T cell immunotherapy by combining RNAi technology to suppress genes that may impede CAR functionality.
LEARN MORE NOVEL TECHNOLOGY
NEW SOLUTION
Canine CAR-T Therapy Development: From early target discovery, CAR design and construction, cell culture, and transfection, to in vitro and in vivo function validation.
LEARN MORE SOLUTION
